US2011105620A1PendingUtilityA1

Organic compounds

50
Assignee: OOMURA TOMOYUKIPriority: Apr 8, 2003Filed: Jan 10, 2011Published: May 5, 2011
Est. expiryApr 8, 2023(expired)· nominal 20-yr term from priority
Inventors:Tomoyuki OomuraMadhusudhan PudipeddiColleen RueggerAlan Edward RoyceMasaki SasakiTokuhiro Tamura
A61P 37/02A61P 37/00A61P 37/06A61P 43/00A61P 41/00A61P 9/00A61P 31/00A61P 25/00A61P 25/28A61P 29/00A61P 31/12A61K 9/2054A61K 9/0053A61K 9/4858A61K 9/2018A61K 9/4866A61K 31/135A61K 31/138A61K 45/06A61K 9/2013A61K 47/26A61K 31/145A61K 31/137A61K 47/10A61K 9/48A61K 9/20
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol.

Claims

exact text as granted — not AI-modified
1 . A solid pharmaceutical composition suitable for oral administration, comprising:
 (a) a S1P receptor agonist; and   (b) a sugar alcohol.   
     
     
         2 . A composition according to  claim 1 , wherein the S1P receptor agonist comprises 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or 2-amino-2-{2-[4-(1-oxo-5-phenylpentyl)-phenyl]ethyl}propane-1,3-diol or a pharmaceutically acceptable salt thereof. 
     
     
         3 . A composition according to  claim 1  or  claim 2 , wherein the sugar alcohol comprises mannitol. 
     
     
         4 . A composition according to any preceding claim, further comprising a lubricant. 
     
     
         5 . A composition according to  claim 4 , wherein the lubricant comprises magnesium stearate. 
     
     
         6 . A composition according to any preceding claim, comprising 0.5 to 5% by weight of the S1P receptor agonist. 
     
     
         7 . A composition according to any preceding claim, comprising 90 to 99.5% by weight of the sugar alcohol. 
     
     
         8 . A composition according to any of  claims 4  to  7 , comprising 1.5 to 2.5% by weight of the lubricant. 
     
     
         9 . A composition according to any preceding claim, in the form of a tablet. 
     
     
         10 . A composition according to any of  claims 1  to  9  in the form of a capsule.

Join the waitlist — get patent alerts

Track US2011105620A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.